The systemic administration of human recombinant G-CSF needs repeated injections for its’ short circular half-life (3.5–3.8 h) [28], and systemic applications of G-CSF will induce leukocytosis [28]. This evidence concerns the gene CSF3 and Increased total leukocyte count.